GlassScriptPhysician profile
Baker T Boles
NPI 1376957324
$13,059.25
in general payments reported to CMS, 2019-2025
54 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,982 · 2020: $497 · 2021: $1,598 · 2022: $1,900 · 2023: $2,710 · 2024: $2,406 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,064 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,064.38 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,715.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,447.13 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $1,374.44 | 2019-2025 | |
| Novo Nordisk INC | $1,014.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $717.04 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $651.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $564.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $513.37 | 2019-2025 | |
| Abbott Laboratories | $447.71 | 2019-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $389.24 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Gilead Sciences, INC. | $353.84 | 2021-2025 | Biktarvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.79 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $305.05 | 2020-2025 | Nexletol |
| Dexcom, INC. | $260.24 | 2022-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.70 | 2019-2024 | Xifaxan |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $240.71 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $218.83 | 2019-2023 | Xyosted, Qelbree |
| Amarin Pharma, INC. | $214.21 | 2019-2022 | |
| Exact Sciences Corporation | $207.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $179.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $163.66 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $162.83 | 2020-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $138.60 | 2019-2022 | |
| Shionogi INC | $116.31 | 2021-2025 | Fetroja |
| Melinta Therapeutics, LLC | $115.25 | 2022-2024 | Kimyrsa, Vabomere, Rezzayo |
| Biohaven Pharmaceutical Holding Company LTD. | $99.14 | 2022 | |
| Viiv Healthcare Company | $86.00 | 2022-2025 | Rukobia, Dovato |
| Takeda Pharmaceuticals U.S.A., INC. | $82.98 | 2020-2022 | |
| Daiichi Sankyo INC. | $70.57 | 2022-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $70.48 | 2024-2025 | Voquezna |
| Insmed, INC. | $61.69 | 2025 | Brinsupri, Arikayce |
| Halozyme INC | $44.61 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.32 | 2024-2025 | Caplyta |
| Acadia Pharmaceuticals INC | $29.33 | 2021 | |
| Allergan, INC. | $28.04 | 2019-2020 | |
| Eisai INC. | $26.99 | 2021 | |
| Pharmacosmos Therapeutics INC. | $25.85 | 2021 | |
| Alkermes, INC. | $23.02 | 2022 | |
| Inari Medical, INC. | $21.80 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Verona Pharma, INC. | $19.92 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $19.85 | 2021 | |
| Sumitomo Pharma America, INC. | $19.71 | 2023-2024 | Gemtesa |
| Csl Behring | $19.17 | 2024 | Hizentra |
| Inspire Medical Systems, INC. | $19.05 | 2025 | Inspire |
| Vanda Pharmaceuticals INC. | $18.30 | 2025 | Fanapt, Hetlioz |
| La Jolla Pharmaceutical Company | $18.19 | 2025 | Xacduro |
| Lundbeck LLC | $17.82 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $17.08 | 2025 | Nuzyra |
| Lexicon Pharmaceuticals, INC. | $16.97 | 2024 | |
| Ardelyx, INC. | $16.32 | 2024 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $16.00 | 2023 | Rexulti |
| Dynavax Technologies Corporation | $14.16 | 2024 | Heplisav-B |
| Ironwood Pharmaceuticals, INC | $12.87 | 2019 | |
| Mannkind Corporation | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baker Boles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.